Advertisement
SNDX vs STTK
To compare these two companies we present long-term analysis, their fundamental ratings and make comparative short-term technical analysis which are presented below. The conclusion is SNDX is a Hold and STTK is a Hold.
SNDX's RSI Oscillator is remaining in oversold zone for 4 days
The price of this ticker is presumed to bounce back soon, since the longer the ticker stays in the oversold zone, the more promptly an uptrend is expected.
Technical Analysis (Indicators)
Bullish Trend Analysis
The Stochastic Oscillator demonstrated that the ticker has stayed in the oversold zone for 2 days, which means it's wise to expect a price bounce in the near future.
Following a +1.92% 3-day Advance, the price is estimated to grow further. Considering data from situations where SNDX advanced for three days, in 220 of 274 cases, the price rose further within the following month. The odds of a continued upward trend are 80%.
SNDX may jump back above the lower band and head toward the middle band. Traders may consider buying the stock or exploring call options.
Bearish Trend Analysis
The Momentum Indicator moved below the 0 level on November 04, 2026. You may want to consider selling the stock, shorting the stock, or exploring put options on SNDX as a result. In 76 of 91 cases where the Momentum Indicator fell below 0, the stock fell further within the subsequent month. The odds of a continued downward trend are 84%.
The Moving Average Convergence Divergence Histogram (MACD) for SNDX turned negative on November 04, 2026. This could be a sign that the stock is set to turn lower in the coming weeks. Traders may want to sell the stock or buy put options. Tickeron's A.I.dvisor looked at 40 similar instances when the indicator turned negative. In 34 of the 40 cases the stock turned lower in the days that followed. This puts the odds of success at 85%.
Following a 3-day decline, the stock is projected to fall further. Considering past instances where SNDX declined for three days, the price rose further in 50 of 62 cases within the following month. The odds of a continued downward trend are 77%.
The Aroon Indicator for SNDX entered a downward trend on November 10, 2026. This could indicate a strong downward move is ahead for the stock. Traders may want to consider selling the stock or buying put options.
Fundamental Analysis (Ratings)
The Tickeron PE Growth Rating for this company is 9 (best 1 - 100 worst), pointing to outstanding earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.
The Tickeron Seasonality Score of 75 (best 1 - 100 worst) indicates that the company is slightly overvalued in the industry. The Tickeron Seasonality score describes the variance of predictable price changes around the same period every calendar year. These changes can be tied to a specific month, quarter, holiday or vacation period, as well as a meteorological or growing season.
The Tickeron Price Growth Rating for this company is 91 (best 1 - 100 worst), indicating slightly worse than average price growth. SNDX’s price grows at a lower rate over the last 12 months as compared to S&P 500 index constituents.
The Tickeron Valuation Rating of 93 (best 1 - 100 worst) indicates that the company is significantly overvalued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (56.421) is normal, around the industry mean (3.498). P/E Ratio (-3.801) is within average values for comparable stocks, (-1.193). Projected Growth (PEG Ratio) (0.000) is also within normal values, averaging (9.059). Dividend Yield (0.000) settles around the average of (130.981) among similar stocks. P/S Ratio (6.010) is also within normal values, averaging (440.869).
The Tickeron SMR rating for this company is 100 (best 1 - 100 worst), indicating weak sales and an unprofitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.
The Tickeron Profit vs. Risk Rating rating for this company is 100 (best 1 - 100 worst), indicating that the returns do not compensate for the risks. SNDX’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 93, placing this stock worse than average.
STTK's Stochastic Oscillator remains in oversold zone for 5 days
The price of this ticker is presumed to bounce back soon, since the longer the ticker stays in the oversold zone, the more promptly an uptrend is expected.
Technical Analysis (Indicators)
Bullish Trend Analysis
The RSI Oscillator points to a transition from a downward trend to an upward trend -- in cases where STTK's RSI Indicator exited the oversold zone, 26 of 33 resulted in an increase in price. Tickeron's analysis proposes that the odds of a continued upward trend are 79%.
Following a +11.14% 3-day Advance, the price is estimated to grow further. Considering data from situations where STTK advanced for three days, in 227 of 265 cases, the price rose further within the following month. The odds of a continued upward trend are 86%.
STTK may jump back above the lower band and head toward the middle band. Traders may consider buying the stock or exploring call options.
Bearish Trend Analysis
The Momentum Indicator moved below the 0 level on November 02, 2026. You may want to consider selling the stock, shorting the stock, or exploring put options on STTK as a result. In 83 of 99 cases where the Momentum Indicator fell below 0, the stock fell further within the subsequent month. The odds of a continued downward trend are 84%.
The Moving Average Convergence Divergence Histogram (MACD) for STTK turned negative on November 04, 2026. This could be a sign that the stock is set to turn lower in the coming weeks. Traders may want to sell the stock or buy put options. Tickeron's A.I.dvisor looked at 45 similar instances when the indicator turned negative. In 36 of the 45 cases the stock turned lower in the days that followed. This puts the odds of success at 80%.
The 50-day moving average for STTK moved below the 200-day moving average on November 06, 2026. This could be a long-term bearish signal for the stock as the stock shifts to an downward trend.
Following a 3-day decline, the stock is projected to fall further. Considering past instances where STTK declined for three days, the price rose further in 50 of 62 cases within the following month. The odds of a continued downward trend are 87%.
The Aroon Indicator for STTK entered a downward trend on November 10, 2026. This could indicate a strong downward move is ahead for the stock. Traders may want to consider selling the stock or buying put options.
Fundamental Analysis (Ratings)
The Tickeron PE Growth Rating for this company is 14 (best 1 - 100 worst), pointing to outstanding earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.
The Tickeron Valuation Rating of 23 (best 1 - 100 worst) indicates that the company is slightly undervalued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (2.196) is normal, around the industry mean (3.498). P/E Ratio (-10.500) is within average values for comparable stocks, (-1.193). Projected Growth (PEG Ratio) (0.000) is also within normal values, averaging (9.059). Dividend Yield (0.000) settles around the average of (130.981) among similar stocks. P/S Ratio (625.000) is also within normal values, averaging (440.869).
The Tickeron Price Growth Rating for this company is 56 (best 1 - 100 worst), indicating steady price growth. STTK’s price grows at a higher rate over the last 12 months as compared to S&P 500 index constituents.
The Tickeron Seasonality Score of 85 (best 1 - 100 worst) indicates that the company is significantly overvalued in the industry. The Tickeron Seasonality score describes the variance of predictable price changes around the same period every calendar year. These changes can be tied to a specific month, quarter, holiday or vacation period, as well as a meteorological or growing season.
The Tickeron SMR rating for this company is 97 (best 1 - 100 worst), indicating weak sales and an unprofitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.
The Tickeron Profit vs. Risk Rating rating for this company is 100 (best 1 - 100 worst), indicating that the returns do not compensate for the risks. STTK’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 93, placing this stock worse than average.
SNDX | STTK | ||
|---|---|---|---|
OUTLOOK RATING 1..100 | 58 | 73 | |
VALUATION overvalued / fair valued / undervalued 1..100 | 93 Overvalued | 23 Undervalued | |
PROFIT vs RISK RATING 1..100 | 100 | 100 | |
SMR RATING 1..100 | 100 | 97 | |
PRICE GROWTH RATING 1..100 | 91 | 56 | |
P/E GROWTH RATING 1..100 | 9 | 14 | |
SEASONALITY SCORE 1..100 | 75 | 85 |
Tickeron ratings are formulated such that a rating of 1 designates the most successful stocks in a given industry, while a rating of 100 points to the least successful stocks for that industry.
STTK's Valuation (23) in the null industry is significantly better than the same rating for SNDX (93) in the Biotechnology industry. This means that STTK’s stock grew significantly faster than SNDX’s over the last 12 months.
STTK's Profit vs Risk Rating (100) in the null industry is in the same range as SNDX (100) in the Biotechnology industry. This means that STTK’s stock grew similarly to SNDX’s over the last 12 months.
STTK's SMR Rating (97) in the null industry is in the same range as SNDX (100) in the Biotechnology industry. This means that STTK’s stock grew similarly to SNDX’s over the last 12 months.
STTK's Price Growth Rating (56) in the null industry is somewhat better than the same rating for SNDX (91) in the Biotechnology industry. This means that STTK’s stock grew somewhat faster than SNDX’s over the last 12 months.
SNDX's P/E Growth Rating (9) in the Biotechnology industry is in the same range as STTK (14) in the null industry. This means that SNDX’s stock grew similarly to STTK’s over the last 12 months.
| SNDX | STTK | |
|---|---|---|
| RSI ODDS (%) | 2 days ago 90% | 2 days ago 79% |
| Stochastic ODDS (%) | 2 days ago 71% | 2 days ago 90% |
| Momentum ODDS (%) | 2 days ago 84% | 2 days ago 84% |
| MACD ODDS (%) | 2 days ago 85% | 2 days ago 80% |
| TrendWeek ODDS (%) | 2 days ago 78% | 2 days ago 88% |
| TrendMonth ODDS (%) | 2 days ago 81% | 2 days ago 90% |
| Advances ODDS (%) | 3 days ago 80% | 3 days ago 86% |
| Declines ODDS (%) | 7 days ago 77% | 7 days ago 87% |
| BollingerBands ODDS (%) | 2 days ago 87% | 2 days ago 84% |
| Aroon ODDS (%) | 2 days ago 79% | 2 days ago 90% |
Long-Term Analysis
It is best to consider a long-term outlook for a ticker by using Fundamental Analysis (FA) ratings. The rating of 1 to 100, where 1 is best and 100 is worst, is divided into thirds. The first third (a green rating of 1-33) indicates that the ticker is undervalued; the second third (a grey number between 34 and 66) means that the ticker is valued fairly; and the last third (red number of 67 to 100) reflects that the ticker is overvalued. We use an FA Score to show how many ratings show the ticker to be undervalued (green) or overvalued (red).
SNDX’s FA Score shows that 1 FA rating(s) are green while STTK’s FA Score has 2 green FA rating(s).
- SNDX’s FA Score: 1 green, 4 red.
- STTK’s FA Score: 2 green, 3 red.
Short-Term Analysis
It is best to consider a short-term outlook for a ticker by using Technical Analysis (TA) indicators. We use Odds of Success as the percentage of outcomes which confirm successful trade signals in the past.
If the Odds of Success (the likelihood of the continuation of a trend) for each indicator are greater than 50%, then the generated signal is confirmed. A green percentage from 90% to 51% indicates that the ticker is in a bullish trend. A red percentage from 90% - 51% indicates that the ticker is in a bearish trend. All grey percentages are below 50% and are considered not to confirm the trend signal.
SNDX’s TA Score shows that 4 TA indicator(s) are bullish while STTK’s TA Score has 4 bullish TA indicator(s).
- SNDX’s TA Score: 4 bullish, 4 bearish.
- STTK’s TA Score: 4 bullish, 5 bearish.
Price Growth
SNDX (@Biotechnology) experienced а -33.59% price change this week, while STTK (@Biotechnology) price change was -11.33% for the same time period.
The average weekly price growth across all stocks in the @Biotechnology industry was +4.90%. For the same industry, the average monthly price growth was -2.72%, and the average quarterly price growth was -13.41%.
Reported Earning Dates
SNDX is expected to report earnings on Mar 02, 2027.
STTK is expected to report earnings on Mar 16, 2027.
Industries' Descriptions
@Biotechnology (+4.90% weekly)Biotechnology involves genetic or protein engineering to produce medicines/therapies for treating and preventing ailments. The industry also provides crucial ingredients for diagnostics. This multi-billion-dollar industry is heavily focused on research and development, as companies attempt to continually come up with cutting-edge solutions for health. New discoveries for the treatment of diseases provide opportunities for growth for a company in this industry. Discoveries, however, must pass the regulatory approval from the U.S. Food and Drug Administration (FDA) before they can make it to markets. Amgen Inc., Gilead Sciences, Inc. and Celgene Corporation are examples of companies in this industry.
Advertisement
SNDX and
Correlation & Price change
A.I.dvisor indicates that over the last year, SNDX has been loosely correlated with KURA. These tickers have moved in lockstep 64% of the time. This A.I.-generated data suggests there is some statistical probability that if SNDX jumps, then KURA could also see price increases.
| Ticker / NAME | Correlation To SNDX | 1D Price Change % | ||
|---|---|---|---|---|
| SNDX | 100% | -0.63% | ||
| KURA - SNDX | 64% Loosely correlated | N/A | ||
| NRIX - SNDX | 55% Loosely correlated | -1.61% | ||
| REPL - SNDX | 51% Loosely correlated | +4.58% | ||
| CGEM - SNDX | 47% Loosely correlated | -4.26% | ||
| VCYT - SNDX | 45% Loosely correlated | -7.18% | ||
More | ||||
STTK and
Correlation & Price change
A.I.dvisor indicates that over the last year, STTK has been loosely correlated with GHRS. These tickers have moved in lockstep 44% of the time. This A.I.-generated data suggests there is some statistical probability that if STTK jumps, then GHRS could also see price increases.
| Ticker / NAME | Correlation To STTK | 1D Price Change % | ||
|---|---|---|---|---|
| STTK | 100% | -2.81% | ||
| GHRS - STTK | 44% Loosely correlated | +1.56% | ||
| TRVI - STTK | 43% Loosely correlated | -2.61% | ||
| SLDB - STTK | 41% Loosely correlated | +2.14% | ||
| SNDX - STTK | 39% Loosely correlated | -0.63% | ||
| WHWK - STTK | 38% Loosely correlated | -4.35% | ||
More | ||||